UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Hamilton James C
   (Last) (First) (Middle)
   177 EAST COLORADO BLVD
   SUITE 700
   PASADENA CA 91105

2. Issuer Name and Ticker or Trading Symbol
   ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

3. Date of Earliest Transaction (Month/Day/Year)
   01/05/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer
   Director
   10% Owner
   Senior Vice President
   Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 5)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>01/05/2021</td>
<td>$ (1)</td>
<td>3,800</td>
<td>D</td>
<td>$71.09(1)</td>
<td>171,200</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/05/2021</td>
<td>$ (1)</td>
<td>3,300</td>
<td>D</td>
<td>$72.19(1)</td>
<td>167,900</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/05/2021</td>
<td>$ (1)</td>
<td>10,350</td>
<td>D</td>
<td>$72.91(1)</td>
<td>157,550</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/05/2021</td>
<td>$ (1)</td>
<td>1,925</td>
<td>D</td>
<td>$73.93(1)</td>
<td>155,625</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/06/2021</td>
<td>$ (1)</td>
<td>700</td>
<td>D</td>
<td>$70.89(1)</td>
<td>154,925</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/06/2021</td>
<td>$ (1)</td>
<td>3,967</td>
<td>D</td>
<td>$72.05(1)</td>
<td>150,958</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>01/06/2021</td>
<td>$ (1)</td>
<td>14,708</td>
<td>D</td>
<td>$72.67(1)</td>
<td>136,250</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 5)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Explanation of Responses:

1. Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units.
2. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.52 to $71.50, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
3. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.57 to $72.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
4. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.60 to $73.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
5. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
6. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.26 to $71.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
7. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.42 to $72.42, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
8. The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.43 to $72.89, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

Remarks:

/s/ James C. Hamilton
01/07/2021

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).